LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

Search

Sage Therapeutics Inc

Cerrado

SectorSalud

6.6 -2.37

Resumen

Variación precio

24h

Actual

Mínimo

6.5

Máximo

6.76

Métricas clave

By Trading Economics

Ingresos

34M

-62M

Ventas

1.2M

14M

BPA

-0.998

Margen de beneficio

-442.395

Empleados

353

EBITDA

13M

-67M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+29.25% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-60M

426M

Apertura anterior

8.97

Cierre anterior

6.6

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

368 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Sage Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 jun 2025, 20:41 UTC

Ganancias

Adobe Raises Outlook After 2Q Sales Beat

12 jun 2025, 23:50 UTC

Ganancias

Adobe Keeps Pivoting as AI Transforms Customer Needs -- Update

12 jun 2025, 23:50 UTC

Ganancias

Adobe Customer Demand Shifting Toward Idea Generation, CFO Says

12 jun 2025, 23:50 UTC

Ganancias

Adobe FireFly Products Drove Revenue Beat in 2Q, CFO Says

12 jun 2025, 23:48 UTC

Charlas de Mercado

Gold Steady Amid Geopolitical Risks -- Market Talk

12 jun 2025, 23:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 jun 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

12 jun 2025, 21:26 UTC

Ganancias

Friedman Industries 4Q Sales $129.2M >FRD

12 jun 2025, 21:25 UTC

Ganancias

Friedman Industries 4Q EPS 76c >FRD

12 jun 2025, 21:11 UTC

Ganancias

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 jun 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 jun 2025, 20:31 UTC

Ganancias

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 jun 2025, 20:30 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Chime IPO: Stock Soars in Nasdaq Debut, Valuing It at Nearly $14 Billion -- Barrons.com

12 jun 2025, 20:15 UTC

Ganancias

Adobe Sees FY25 Rev $23.5B-$23.6B >ADBE

12 jun 2025, 20:15 UTC

Ganancias

Adobe Sees 3Q Rev $5.88B-$5.93B >ADBE

12 jun 2025, 20:14 UTC

Ganancias

Adobe Stock Pops as Earnings Beat Estimates -- Barrons.com

12 jun 2025, 20:07 UTC

Ganancias

Adobe Raises FY25 Rev and EPS Targets

12 jun 2025, 20:05 UTC

Ganancias

Adobe Sees FY Adj EPS $20.50-Adj EPS $20.70 >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe 2Q Digital Experience Revenue $1.46B >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe 2Q Digital Media Revenue $4.35B >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe Sees 3Q EPS $4.00-EPS $4.05 >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe 2Q Net $1.69B >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe 2Q EPS $3.94 >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe 2Q Digital Experience Revenue Up 10% >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe 2Q Rev $5.87B >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe Sees 3Q Adj EPS $5.15-Adj EPS $5.20 >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe Sees FY EPS $16.30-EPS $16.50 >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe 2Q Digital Media Revenue Up 11% >ADBE

12 jun 2025, 20:05 UTC

Ganancias

Adobe 2Q Adj EPS $5.06 >ADBE

Comparación entre iguales

Cambio de precio

Sage Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

29.25% repunte

Estimación a 12 meses

Media 8.75 USD  29.25%

Máximo 12 USD

Mínimo 5 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sage Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

14 ratings

2

Comprar

11

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 7.285Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.